Collagen Market: Competitive Landscape, Pipeline, and Market Analysis 2023

Purchase Option

$ 4400
$ 6600
$ 8900

Collagen is the most abundant protein found in the animal kingdom. It is produced by the fibroblasts and is a structural protein. 28 types of collagens are known, with type 1 accounting for about 90% of the collagen in the human body. Structurally it is a triple-helix composed of 3 amino acids, namely Glycine, Proline, and Hydroxyproline. Collagen is present in many parts of the human body and is found in the connective tissues, bones, cartilage, tendons, ligaments, and skin. It has many roles in the human body, including many cellular processes like cellular communication, cellular migration, tissue repair, and immune response. There are many sources of collagen, including animal skin, bones and ligaments, and seafood.  Collagen supplements are also available in the market for consumption in deficient people. It is used for many indications, so companies are trying to find new and novel molecules to prevent and cure diseases. The development and launch of newer products by the market players will significantly enhance the revenue of the Collagen market over the forecast years. Peyronie’s disease (PD) is a connective tissue disorder in which plaque forms in the Tunica Albuginea layer beneath the skin of the penis resulting in the bending of the penis and causing a painful erection. According to a research article, the prevalence rates ranging between 0.4% to 20.3% are present with considerable variation depending upon age, color, race, and co-morbidities. Thus, there is an opportunity for the market players in the market.

Several of these inhibitors are on the market, while many are in ongoing clinical trials. Various companies have various products in their pipelines, with 21 products in various stages of clinical trials. 2 products in Phase 4, 1 product in Phase 3, 7 products in Phase 2, and 1 product in Phase 1 of the clinical trials.

Approved molecules

  • Xiaflex (collagenase clostridium histolyticum)
  • Rizaben (tranilast)

Drugs in Pipeline

  • Fezagepras (PBI-4050)
  • Hydronidone (F351)
  • Aerodone (Aerosol Pirfenidone)
  • PTR-01
  • TPX-100
  • Tempostatin (Halofuginone)
  • Deuterium Pirfenidone (LYT-100)
  • Remlarsen (MRG-201)
  • Pirfenidone Inhalation (S-770108 Inhalation)

Clinical Activity and Developments of Collagen

As of June 2023, various companies have approximately 21 products for 228 diseases. For these diseases, many trials are being conducted by players globally. For instance,

  • In March 2022, Datum Dental Ltd completed a Phase 4 clinical trial to study the histological evaluation of healing following Ridge preservation using a composite bovine-derived xenograft or a Hydroxyapatite Collagen Matrix.
  • In December 2020, Men’s Health Boston completed a Phase 4 clinical pilot study to study the effect of testosterone treatment in patients who are undergoing Xiaflex therapy for the treatment of Peyronie’s Disease.
  • In August 2020, Hasanuddin University completed a Phase 4 clinical trial to study the Prolotherapy intervention effect in patients with Knee Osteoarthritis.
  • In March 2020, Yonsei University completed a Phase 4 clinical trial to study the Collagen-thrombin Matrix efficacy during cardiac surgery.

Molecule name

Number of studies

Xiaflex (collagenase clostridium histolyticum)


Rizaben (tranilast)


fezagepras (PBI-4050)


hydronidone (F351)


Aerodone (aerosol pirfenidone)



Target Indication Analysis of Collagen

Drugs like Xiaflex (collagenase clostridium histolyticum) and Rizaben (tranilast) are approved by various regulatory agencies for many indications around the globe. Xiaflex has been approved for many indications like Peyronie’s disorder, Musculoskeletal disorders, Hypersensitivity reactions, respiratory hypersensitivity, nose diseases, Rhinitis, and others, while Rizaben (tranilast) is an anti-allergic medication used to treat many indications like Bronchial Asthma, Allergic Rhinitis, Atopic dermatitis, keloid, and others. These are in various phases of the clinical trials for many other indications for which it could be a possible treatment. As the prevalence rates of diseases have been rising for many years, it is an excellent opportunity for the market players.

Frequently Asked Questions

Xiaflex (collagenase clostridium histolyticum) and Rizaben (tranilast) are approved by the FDA and other regulatory agencies across the globe for various indications.

These are used in various indications like Peyronie’s disease, allergy, Hypersensitivity, Musculoskeletal diseases, and others.

Asahi Kasei Pharma Corporation (Japan), Swedish Orphan Biovitrum AB (Sweden), Endo International Plc (USA), Kissei Pharmaceuticals Co., Ltd. (Japan), and Nuon Therapeutics (USA) are some of the major market players for Collagen.

Rising incidence of diseases, improvement in technologies, development of new treatment lines in the market, and changing lifestyles are the key opportunities for Collagen in the market.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
  • Asahi Kasei Pharma Corporation (Japan)
  • Swedish Orphan Biovitrum AB (Sweden)
  • Endo International Plc (USA)
  • Kissei Pharmaceuticals Co., Ltd. (Japan)
  • Nuon Therapeutics (USA)
  • Liminal BioSciences Inc (Canada)
  • Catalyst Biosciences (USA)
  • Avalyn Pharma Inc (USA)
  • BridgeBio Inc (Switzerland)
  • OrthoTrophix, Inc. (USA)
  • Grunenthal (Germany)
  • Akashi Therapeutics Inc (USA)
  • PureTech Health (USA)
  • Viridian Therapeutics, Inc. (USA)
  • Shionogi Inc (Japan)

Adjacent Markets